Neutralizing antibodies (NAbs) targeting glycoprotein E2 are important for the control of hepatitis C virus (HCV) infection. One conserved antigenic site (amino acids 412 to 423) is disordered in the reported E2 structure, but a synthetic peptide mimicking this site forms a ␤-hairpin in complex with three independent NAbs. Our structure of the same peptide in complex with NAb 3/11 demonstrates a strikingly different extended conformation. We also show that residues 412 to 423 are essential for virus entry but not for E2 folding. Together with the neutralizing capacity of the 3/11 Fab fragment, this indicates an unexpected structural flexibility within this epitope. NAbs 3/11 and AP33 (recognizing the extended and ␤-hairpin conformations, respectively) display similar neutralizing activities despite converse binding kinetics. Our results suggest that HCV utilizes conformational flexibility as an immune evasion strategy, contributing to the limited immunogenicity of this epitope in patients, similar to the conformational flexibility described for other enveloped and nonenveloped viruses. A n estimated 180 million people worldwide are infected by hepatitis C virus (HCV), and the majority of infected patients (70 to 80%) develop chronic infection that leads to progressive liver disease (1). Major advances in HCV therapy during the last decade resulted in combination therapies consisting of direct-acting antivirals (DAAs) with sustained virological response rates of Ͼ90% (reviewed in reference 2). Nevertheless, the lack of availability of this HCV therapy in developing countries illustrates the urgent need to design a safe and efficient HCV vaccine, a process that is hampered by our limited understanding of the key epitopes inducing a protective neutralizing immune response.
A n estimated 180 million people worldwide are infected by hepatitis C virus (HCV), and the majority of infected patients (70 to 80%) develop chronic infection that leads to progressive liver disease (1) . Major advances in HCV therapy during the last decade resulted in combination therapies consisting of direct-acting antivirals (DAAs) with sustained virological response rates of Ͼ90% (reviewed in reference 2). Nevertheless, the lack of availability of this HCV therapy in developing countries illustrates the urgent need to design a safe and efficient HCV vaccine, a process that is hampered by our limited understanding of the key epitopes inducing a protective neutralizing immune response.
The majority of neutralizing antibodies (NAbs) identified to date target the major envelope glycoprotein E2 (reviewed in reference 3), which binds the cellular receptors CD81 and scavenger receptor BI (SR-BI) (4, 5) . The glycoprotein contains hypervariable regions (HVRs), termed HVR1, HVR2, and igVR (intergenotypic variable region) (6, 7) , the deletion of which does not affect the overall glycoprotein conformation. The structurally flexible HVR1 located at the N terminus of E2 (8) is dispensable for virus infectivity in chimpanzees (9) . Recent structural studies have shown that HCV E2 has a core fragment with an Ig superfamily fold flanked by a front layer and a back layer containing ␤-sheets, random coils, and short ␣-helices (10, 11) . Of note, both structures were obtained by using an E2 fragment lacking HVR1; thus, an interaction of HVR1 with the E2 core cannot be excluded.
The neutralizing antibody AR3C binds to a large part of the front layer (amino acids [aa] 426 to 446) and residues within the CD81 binding loop (aa 528 to 531). Further insights into the recognition of E2 neutralizing epitopes came from structural studies that cocrystallized Fab fragments derived from anti-E2 NAbs recognizing two regions comprising residues 430 to 446 and 412 to 423, respectively, in complex with their respective epitope peptides (12) (13) (14) (15) (16) (17) (18) . In these complexes, the peptide comprising aa 430 to 446 adopts a short ␣-helical conformation, with extended segments in either direction (12, 16) , and was proposed to adopt two discrete conformations in the context of the viral particle based on these peptide structures (11, 13) . The segment comprising aa 412 to 423 adopts a ␤-hairpin in complex with three independent broadly neutralizing antibodies (HCV1, AP33, and Hu5B3.v3), suggesting a flexible flap-like structure (14, 15, 17, 18) . The antigenic site spanning aa 412 to 423 contains highly conserved epitopes targeted by monoclonal antibodies (MAbs) neutralizing HCV strains of all major genotypes (19) (20) (21) (22) (23) and is positioned downstream of HVR1. All described epitopes include a tryptophan residue at position 420 that plays a critical role in CD81 recognition (24) ; nonetheless, a surprisingly weak immune response against this antigenic site was reported for infected patients (22, 25) .
Here we report the crystal structure of the epitope comprising aa 412 to 423 in complex with the neutralizing anti-HCV E2 antibody 3/11, unexpectedly revealing an extended peptide conformation that is strikingly different from the previously reported ␤-hairpin. We demonstrate that the segment spanning aa 412 to 423 is not required for the native overall fold of a soluble E2 (sE2) ectodomain but is essential for the infectivity of HCV pseudoparticles (HCVpp) and cell culture-derived HCV (HCVcc). A comparative functional analysis of Fab fragments derived from NAbs 3/11 and AP33, exemplary for NAbs recognizing the ␤-hairpin, reveals similar neutralization activities for both NAbs and Fab fragments in spite of strikingly different binding kinetics. In combination with the neutralizing activity of MAb 3/11, our results illustrate the structural flexibility of this region within HCV E2 and provide novel insights into the recognition of conserved neutralizing epitopes, with implications for vaccine design.
MATERIALS AND METHODS

Production and purification of recombinant Fabs and glycoproteins.
Synthetic genes of the Fab coding regions of MAbs 3/11 and AP33 were cloned into a Drosophila melanogaster S2 Fab expression vector described previously (26) . The HCV E2 full-length ectodomain (sE2), the ectodomain lacking hypervariable region 1 (sE2 ⌬HVR1) (amino acids 412 to 715 of the HCV polyprotein), and the ectodomain lacking the N-terminal 42 residues (sE2 426 -717 ) from strain UKN2B2.8 (GenBank accession number AY734983) were expressed in Drosophila S2 cells as previously described (27, 28) . Briefly, Drosophila S2 cells were transfected as reported previously (63) , amplified, and induced with 4 M CdCl 2 at a density of ϳ7 ϫ 10 6 cells/ml for 8 days for large-scale production. Proteins were purified from the supernatant by affinity chromatography using a StrepTactin Superflow column followed by size exclusion chromatography (SEC) using a Superdex200 column. Pure monomeric proteins were concentrated to ϳ20 mg/ml.
Neutralizing capacity of recombinant Fab fragments and infectivity of HCVcc and HCVpp ⌬aa384 -425 deletion mutants. HCVcc of H77/ JFH-1 and J6/JFH-1 were produced as previously described (29) . A mutant HCV J6/JFH1 clone lacking HVR1 (aa 384 to 410) was generated by using plasmid pFL-J6/JFH1 as the template (29) and the Q5 site-directed mutagenesis kit (NEB) (primers are available upon request). Huh7.5 cells were cultured in Dulbecco's modified Eagle's medium (DMEM)-10% fetal calf serum (FCS) and harvested at 24, 48, and 72 h following transfections. NS5A expression, as an indirect indicator for replication/translation, was assessed by immunostaining of electroporated cells using MAb 9E10. Supernatants were then used to infect naive cells, and infectivity was assessed by NS5A immunostaining after 48 h.
Neutralization assays were performed by mixing 100 focus-forming units (FFU) of HCVcc in the absence or presence of the indicated concentrations of antibodies for 1 h before addition to Huh7.5 cells (a kind gift from C. Rice, Rockefeller University) and incubation for 72 h at 37°C. Cells were then fixed and stained for NS5A, and the number of infected foci was determined by counting immunofluorescence (IF)-positive cells. The number of infected cells was compared to untreated samples, or to samples in the presence of control IgG, to calculate the percentage of inhibition.
RNA transcripts were produced and electroporated into Huh7.5 cells as previously described (29) . A plasmid encoding the E1/E2 primary isolate UKN1A20.8 (GenBank accession number EU155192) was used as the template for the production of HCV pseudoparticles containing wild-type (wt) or ⌬HVR1 E2, as previously described (30) . Infectivity in Huh7 cells was determined after 48 h by reading the luciferase activity in lysed cells (Promega).
Peptides and complex formation. A synthetic peptide comprising residues 412 to 423 (QLINTNGSWHVN) of genotype 1a strain Glasgow (GenBank accession number AY885238), which differs from the H77 reference sequence by a V 422 I substitution (31) , was synthesized by the American Peptide Company (Ͼ98% purity) and dissolved in water plus 5% dimethyl sulfoxide (DMSO) at 10 mg/ml. A complex containing 1.5 mg/ml peptide plus 9 mg/ml Fab was formed overnight at 293 K.
Crystallization, data collection, structure determination, and refinement. Complex crystals were grown at 293 K by using the hangingdrop vapor diffusion method with drops containing 1 l complex solution (10.6 mg/ml in 10 mM Tris [pH 8.0], 100 mM NaCl) mixed with 1 l reservoir solution. This reservoir solution contained 100 mM Tris (pH 7.5), 27% polyethylene glycol 4000 (PEG 4000), and 100 mM Na-acetate or 100 mM Tris (pH 8.5) and 66% 2-methyl-2,4-pentanediol (MPD) for crystals in space group P1 or P2 1 , respectively. Diffraction quality crystals appeared after 1 week and were flash-frozen in mother liquor with (space group P1) or without (space group P2 1 ) 22% glycerol. Space groups and cell dimensions of the crystals, the number of complexes per asymmetric unit, resolution limits, data collection details, and refinement statistics are summarized in Table 2 .
Data were collected on the beamline Proxima-1 at Synchrotron Soleil, processed, scaled, and reduced by using XDS (32), Pointless (33) , and programs from the CCP4 suite (34) . The crystal structures of the Fab complexes were determined by the molecular replacement method using Phaser (35) . We used separate variable and constant regions of a hypothetical Fab fragment assembled from the best sequence match in the Protein Data Bank (PDB), the light chain (LC) reported under PDB accession number 1NLD and the heavy chain (HC) reported under PDB accession number 3EOT, as a search model for the P2 1 crystals and the refined P2 1 structure as a search model for the P1 crystal form. Model building was performed by using Coot (36) , and refinement was done by using AutoBuster (37) .
Crystal structure analysis. The two peptides derived from the different crystal forms were superposed by using an iterative alignment process pruning long atom pairs until no pair exceeded 0.5 Å, implemented in the MatchMaker algorithm of Chimera (38) and the MultiProt server (39) . Root mean square deviations (RMSDs) between the peptides derived from different crystal forms of the 3/11 complex were calculated either over all atoms per residue or by taking into account only the main-chain atoms (N, CA, C, and O), using Chimera.
Buried solvent-accessible surface areas for the interfaces as well as for individual residues within the peptides were calculated by using the PISA server (40) . Shape complementarity was calculated by using programs of the CCP4 suite (34) . Interactions were determined by using the Protein Interactions Calculator (PIC) (41) . Figures were prepared with Pymol (http://www.pymol.org/).
Surface plasmon resonance analysis. Real-time surface plasmon resonance (SPR) assays were performed by using a Biacore 2000 instrument (GE Healthcare) equilibrated at 25°C in phosphate-buffered saline (PBS) supplemented with 0.1 mg/ml bovine serum albumin (BSA). To determine the affinity of the peptide for Fabs 3/11 and AP33, these Fab frag-ments (in 10 mM acetate [pH 4.5]) were covalently coupled to the carboxy methyl moieties of CM5 sensorchips by using a Biacore 2000 instrument and the Amine Coupling kit (GE Healthcare), achieving immobilization density (R immo ) values of 3,000 to 5,000 resonance units (RU) (1 RU equals 1 pg mm Ϫ2 ). We used Fab e137 (40) as a negative control, because it recognizes an unrelated conformational epitope within HCV E2. A triplicate series of 10 concentrations of peptides (1 to 2,000 nM) was injected over the Fab surfaces and an empty reference flow cell for 5 min at a flow rate of 50 l · min Ϫ1 . After monitoring dissociation for 10 min, the surfaces were regenerated by a 30-s wash with 0.1% SDS. To determine the affinity of native and denatured glycoproteins for the Fab fragments, monoclonal antibody C23.21 directed against Strep-Tag (in 10 mM acetate [pH 5.5]) was covalently coupled to all 4 flow cells of CM5 sensorchips, achieving an R immo of 7,500 to 9,000 RU. Subsequently, full-length or truncated (native or denatured) HCV sE2 of genotype 1a strain H77 was captured via its Strep-Tag to a density of 300 to 400 RU. A series of 10 concentrations of Fabs 3/11 and AP33 (1.5 to 1,500 nM) was injected over the HCV sE2 surfaces and an unliganded C23.21 reference flow cell for 8 min at a flow rate of 30 l · min Ϫ1 . After monitoring dissociation for 5 min, the surfaces were regenerated by two 1-min washes with 10 mM glycine-HCl (pH 2.0) and one wash with 0.1% SDS.
The real-time interaction profiles were double referenced by using Scrubber 2.0 software (BioLogic Software), i.e., the signals from both reference surfaces and blank experiments using PBS-BSA instead of peptide or Fab. The association rate (k on ), dissociation rate (k off ), and the equilibrium dissociation constant (K d ) were determined by using BIAevaluation 4.1 software (GE Healthcare), by globally fitting the processed experimental curves to a 1:1 Langmuir model. To facilitate direct comparisons of the kinetics of binding to different Fab fragments, the binding response was normalized and expressed as the occupancy of binding sites. Pulldown assays. To analyze the conformation of sE2 in complex with Fab 3/11, UKN2b2.8 sE2 ⌬HVR1 was bound to a StrepTactin Superflow minicolumn, followed by an initial washing step. Subsequently, a 3-fold molar excess of Fab 3/11 was added, followed by a second washing step and, afterwards, the addition of a 3-fold molar excess of CBH-4D antibody (collection of human material, Institut Pasteur no. DC-2010-1197/ 7). After extensive washing, the complex was eluted and analyzed by SDS-PAGE and Coomassie blue staining.
To determine the interaction of sE2 426 -717 with conformation-sensitive antibodies and its receptor CD81, sE2 426 -717 was bound to the column, followed by an extensive wash step. Subsequently, a 3-fold molar excess of the large extracellular loop of human CD81 (CD81-LEL) (produced as described previously [5] ), a Fab fragment (e137) (42), or MAb CBH-4D (43) directed against HCV E2 was added. After extensive washing, the complex was eluted and analyzed by SDS-PAGE followed by Coomassie blue staining.
Protein structure accession numbers. The atomic coordinates and structure factors for two crystal structures were deposited in the Protein Data Bank (http://www.pdb.org/) under accession numbers 4WHT and 4WHY.
RESULTS AND DISCUSSION
Crystallization of the Fab-peptide complex and structure determination. We expressed the Fab fragments derived from MAbs 3/11 and AP33 (the latter one was used as the control throughout this study) in Drosophila S2 cells. Both Fab fragments were able to neutralize cell culture-derived HCV (HCVcc) harboring HCV envelope glycoproteins of genotypes 1a (strain H77) and 2a (strain J6) in a dose-dependent manner albeit slightly less efficiently than the parental antibodies, reflecting the reduced avidity of the Fab fragments ( Fig. 1 and Table 1 ). We performed cocrystallization trials for a complex containing Fab 3/11 and a peptide comprising residues 412 to 423 (QLINTNGSWHVN) of genotype 1a strain Glasgow and obtained diffraction quality crystals in two different space groups (P1 and P2 1 , respectively) ( Table 2 ). The peptide sequence used in this study was chosen because it was previously used for cocrystallization with Fab AP33 (18) . The structure of the Fab 3/11-peptide complex was determined by the molecular replacement method ( Fig. 2A) , using the variable and constant regions of unrelated Fab fragments as separate search models (see Materials and Methods) in the P2 1 crystal form. Difference maps calculated after refinement of the recombinant Fab molecules revealed well-defined electron density for the peptide, which allowed manual building of an atomic model for the peptide (Fig.  3A) . The resulting structure of the Fab 3/11-peptide complex is displayed in Fig. 2A , with Fab 3/11 being almost planar, with an elbow angle of 171.7°. The peptide conformation is identical in all complexes in the asymmetric unit (4 and 12 complexes in space groups P2 1 and P1, respectively). For further analysis, the peptide comprising all residues with the lowest mean B value after crystallographic refinement, indicating the highest degree of order in this part of the structure, from the higher-resolution structure (space group P1) was selected.
Molecular determinants of the Fab 3/11 interaction with its peptide epitope. The peptide corresponding to residues 412 to 423 binds to Fab 3/11 in an extended conformation that is deeply immersed within the cleft between the heavy and light chains ( , respectively) and a shape complementarity index of 0.78. The N-terminal part of the peptide interacts mostly with the light chain, and its C-terminal part makes a right-angle turn around complementarity-determining region 2 of the heavy chain (CDR-H2). The central part of the peptide comprising residues N 415 to S 419 bulges out, resulting in the side chains of N 417 and S 419 being exposed (Fig. 2C) . Because the side chain of N 423 is also exposed, this overall peptide conformation is in line with the fact that N 417 and N 423 represent N-linked glycosylation sites (44) , which, in the context of the infectious virus particle, need to accommodate the two Nlinked glycans and therefore may not be involved in the antibody binding face of the epitope (Fig. 4A) (Fig. 3B) . Analysis of the mean temperature factors (B-factors) per residue (calculated over the main chain and over all atoms) suggested a higher degree of disorder at both ends of the peptide (Fig. 3C) . The high B-factor value calculated over all atoms of N 417 compared to its main-chain B-factor value suggests a greater flexibility of the side chain, in agreement with its role as an attachment site for an N-linked glycan.
A aspartic acid and E31 within the CDR-L1 (E L31 ). Given that 95% of the solvent-accessible surface of N 415 is buried, the interface between 3/11 and E2 cannot accommodate bulky amino acids larger than asparagine at this position, explaining why the N 415 Y mutation abolishes virus neutralization by 3/11 (46) . The N 417 S mutation shifts the N-linked glycosylation site from N 417 to N 415 (17) , where the glycan chain cannot be accommodated within the interface. These results indicate an antibody-antigen complex interface that is dominated by residues N 415 , W 420 , and H 421 , in line with data from our previously reported alanine scanning mutagenesis analysis (20) , supporting the notion that our structure reflects the native antibody-antigen interaction.
Conformation of the E2 peptide comprising aa 412 to 423. In spite of the extended conformation, the bulge at the peptide center results in the same overall number of backbone hydrogen bonds found in the ␤-hairpin; however, no similarities between hydrogen bonding networks or the corresponding peptide conformations were observed (Fig. 3) . In solution, the peptide is likely to adopt several different conformations that are in equilibrium, and different antibodies bind to it according to the principle of conformational selection. All four antibodies for which the peptide structure has been reported (HCV1, AP33, Hu5B3.v3, and 3/11) neutralize HCV infection (i.e., they bind to their respective epitopes at the surface of infectious virions), suggesting that the peptide spanning aa 412 to 423 adopts different conformations. Our structure therefore illustrates that the previously reported structural flexibility of HVR1 (8) extends to the downstream neutralizing antigenic site (aa 412 to 423), in line with the recently reported increased deuterium exchange rate in the context of a soluble E2 ectodomain (10) . The fact that all four antibodies neutralize HCV infection by inhibiting the E2-CD81 interaction (19, 21, 47) suggests that both conformations can be accessible at the virus surface, likely in a dynamic equilibrium that can be shifted into either direction by antibody binding. The dose-dependent neutralization of both MAbs 3/11 and AP33 (Ͼ98% of HCVcc H77) (Fig. 1A) supports this hypothesis. Our results suggest that any of the four antibodies binding to aa 412 to 423 at the virus surface will contribute to neutralization by shifting the equilibrium into the respective direction.
One possible explanation for the observed difference in peptide conformations is that the epitope structure depends on the polypeptide sequence up-and/or downstream of the antigenic site, implying that different strains/isolates present the epitope in different conformations. Evidence for such a strain-specific modulation of neutralization profiles was reported for a group of broadly neutralizing human MAbs targeting aa 412 to 423 (HC33 antibodies) in spite of an identical amino acid sequence within this site (22) . It should be noted, however, that NAbs targeting this antigenic site neutralize a broad range of HCV genotypes independent of the recognized conformation (19, 20) , suggesting that the isolate-specific amino acid sequences are unlikely to determine the conformation of the antigenic site spanning aa 412 to 423 but rather modulate the neutralization efficiency by minor changes in epitope presentation.
Another possible explanation could be a conformational change that E2, in particular the antigenic site spanning aa 412 to 423, undergoes during virus entry, suggesting that the two conformations may represent snapshots of the same region at different functional stages of the entry process. All four antibodies (HCV1, AP33, Hu5B3.v3, and 3/11) neutralize HCV infection by interfering with CD81 binding (19, 21, 47) , suggesting that they all neutralize HCV upstream of the E2-CD81 interaction. However, a more detailed interpretation will require further experiments to analyze MAb interactions with infectious virus particles in a quantitative and time-resolved manner (e.g., by precipitation).
Affinity of Fabs 3/11 and AP33 for their epitope peptide and native soluble E2. To further investigate the role of the distinct epitope conformations in antigen binding, we determined the equilibrium dissociation constants (K d ) as well as association (k on ) and dissociation (k off ) rates for the binding of Fabs 3/11 and AP33 to the monomeric full-length E2 ectodomain (wt sE2) and epitope peptides by surface plasmon resonance (SPR). SPR analysis was performed by using the crystallized peptide as well as the corresponding peptide derived from the H77 reference strain to allow direct comparison of peptide and sE2 binding kinetics and revealed no major differences in binding kinetics between the two peptides, in line with the facts that the V 422 I substitution is the only difference between the two peptides and that I 422 is not a major determinant of the Fab binding interface. The affinity of Fab 3/11 for the H77 peptide was ϳ10-fold higher than that for sE2 of strain H77 (K d values of 6.5 nM and 65 nM for the peptide and sE2, respectively) ( Table 3 and Fig. 5 ), suggesting that the extended conformation observed in our structure can be adopted more easily by the peptide than by sE2, likely due to the presence of the surrounding N-and C-terminal polypeptide chains. Similar values for glycoprotein-Fab affinity were observed with inversed SPR settings with the Fab fragment covalently coupled to the surface (data not shown), confirming the obtained kinetic parameters. The relatively slow association and high stability of the complex are in line with the peptide being deeply immersed into the (40), represented per residue as stacked columns for heavy (dark gray) and light (light gray) chains of Fab 3/11. (C) Average temperature factor values after crystallographic refinement of the peptide plotted per residue (light gray) and taking into account only backbone atoms (dark gray) illustrate that only the terminal peptide residues are less ordered, suggesting that they contribute less to antigen binding. In addition, the side chain of N 417 , the only really exposed residue, displays a higher temperature factor value. (D and E) The paratope of Fab 3/11 is shown as a molecular surface, and its peptide epitope is shown as sticks, colored as described above for panel A. The molecular surface of the paratope is colored according to its electrostatic potential (Ϫ5 kT/e [red] to 5 kT/e [blue]) across the molecular surface of the paratope, calculated by using the adaptive Poisson-Boltzmann solver (D) or according to a normalized hydrophobicity scale from white (hydrophobic) to bright yellow (hydrophilic) (E).
cleft between the heavy and light chains. Fab AP33 bound the peptide with a lower affinity than did Fab 3/11 (K d , 50.9 nM) but bound wt sE2 with an ϳ2-fold-higher affinity (K d , 38 nM). The binding was in both cases characterized by faster association and dissociation than for Fab 3/11 (Table 3) . A closer look at the kinetic parameters revealed that Fab 3/11 dissociates more slowly from its antigen than does Fab AP33, whereas Fab AP33 associates with its antigen faster than does Fab 3/11 ( Fig. 5B and C) . One possible explanation for these differences in kinetic parameters could be a high prevalence of the ␤-hairpin, compared to the low prevalence of the extended conformation, although quantitative binding experiments using Fab and infectious virus particles are necessary to support this hypothesis. These differences in binding kinetics may explain the apparent contradiction in previous affinity comparisons of the two antibodies obtained by an enzymelinked immunosorbent assay (ELISA)-based method using IgG (20) , which likely detected a higher k on of AP33 than of 3/11 but failed to account for k off values. Alternatively, the bivalency of the antibody could compensate for the lower stability of the AP33 complex, whereas it does not affect the lower association rate of 3/11. In summary, we observed similar overall affinities for the binding of both Fabs to wt sE2, but kinetic binding analysis revealed marked differences in association and dissociation rates.
The kinetic binding parameters together with the ϳ2-foldhigher neutralization potency of MAb AP33 (Fig. 1A and Table 1) suggest that the latter is determined mainly by the higher on-rate. A similar relationship between kinetic binding parameters and biological activity was reported for affinity-maturated Fab molecules against envelope protein F of respiratory syncytial virus (RSV), where k on was the crucial kinetic parameter that determined the biological activity of the IgG molecules, whereas slow dissociation increased the overall affinity but did not improve the neutralizing capacity (48, 49) . For other antibodies, a direct link between a lower k off rate and improved biological activity has been established (50) (51) (52) , but the correlation is not necessarily linear (50) , and in some cases, only specificity determines the biological activity, in spite of a low binding affinity (53) .
An important role in shielding neutralizing epitopes, in particular of the CD81 binding site, has been attributed to HVR1 (54, 55) . To analyze the contribution of this region to Fab binding and neutralization, we first determined the kinetic parameters for the interaction between Fabs 3/11 and AP33 and an E2 ectodomain lacking HVR1 (encoding H77 aa 412 to 717) (sE2 ⌬HVR1). Fab 3/11 bound to the mutant with an affinity similar to that for the peptide (K d , 26 nM) and with a 4-fold-higher association rate than that for wt sE2, suggesting that the presence of HVR1 restricts Fab 3/11 binding to wt sE2. In contrast, Fab AP33 bound sE2 ⌬HVR1 with a 2.5-fold-lower affinity than that for the wt glycoprotein due to a higher dissociation rate (Table 3 and Fig. 5B and C) . These results suggest that the presence of HVR1, while hampering Fab 3/11 binding to wt sE2, contributed to the stability of the AP33-glycoprotein complex. This could be due to additional contact residues or a direct stabilizing effect of HVR1 on the ␤-hairpin.
MAbs and patient sera targeting the CD81 binding site within E2 neutralize ⌬HVR1 HCVcc more efficiently than they neutralize wt virus (54) . Surprisingly, the neutralizing activities of Fab 3/11, but not that of MAb 3/11, were almost identical for both wt and ⌬HVR1 viruses (Fig. 1B) , despite the faster association with sE2 ⌬HVR1. Similarly, while both Fab AP33 and MAb AP33 neutralized ⌬HVR1 virus more efficiently than they neutralized wt virus (Fig. 1B) , this difference was more pronounced for MAb AP33 (ϳ9-fold) than for the Fab fragment (ϳ2-fold). These results suggest that, independent of the kinetic binding parameters, bivalent IgG molecules neutralize ⌬HVR1 virus more efficiently than do and Fab HCV1 (C) (15) , as an example of the ␤-hairpin conformation of aa 412 to 423, are shown as sticks and colored by atom type (green, red, and blue for carbon, oxygen, and nitrogen, respectively) to illustrate the differences in the backbone conformations observed for the two structures. The five hydrogen bonds stabilizing the backbone conformation in both structures are indicated as dotted lines.
the corresponding monovalent Fab molecules, whereas for wt virus, this appears to depend on the particular NAb. Of note, corresponding IgG and Fab molecules do not necessarily utilize identical neutralization mechanisms (56) . In summary, our results support a model in which the removal of HVR1 results in increased exposure of the CD81 binding site, an effect that is likely to be more pronounced for larger MAbs (molecular mass of ϳ150 kDa) than for smaller Fab molecules (molecular mass of ϳ50 kDa).
Requirement of aa 412 to 423 for protein folding and infectivity. The very low RMSD of 0.8 Å between C ␣ atoms of the two E2 core fragments, one containing and one lacking the 44 residues downstream of HVR1 (aa 412 to 456) (10, 11) , indicates that this region is not required for E2 folding and therefore that the binding of MAb 3/11 is unlikely to affect the overall fold of E2. To test this hypothesis, we determined the binding of the conformation-sensitive, nonneutralizing human antibody CBH-4D (43) to a Fab 3/11-sE2 ⌬HVR1 complex by a coprecipitation assay. SDS-PAGE analysis of the eluted fractions demonstrated that sE2 ⌬HVR1 in complex with Fab 3/11 efficiently bound the CBH-4D antibody (Fig. 6A ), indicating that 3/11 binding does not affect the overall fold of the glycoprotein. Deletion of the N-terminal 72 residues of E2 abolishes binding to its cellular receptor CD81 (10), whereas deletion of HVR1 does not affect CD81 binding (7) . To analyze the role of aa 412 to 423, we expressed recombinant soluble E2 lacking the N-terminal 42 residues (encoding aa 426 to 717) (sE2 426 -717 ). As anticipated, size exclusion chromatography (SEC) analysis revealed a majority of the purified protein eluting at a volume corresponding to a monomer, confirming that the deletion of aa 412 to 425 does not lead to multimer formation via nonproper interchain disulfides and therefore likely does not impair protein folding (Fig. 6B) . To analyze the adopted conformation of the deletion mutant, we used pulldown assays to analyze the interaction of sE2 426 -717 with the soluble portion of CD81 (CD81-LEL) and Fab fragments derived from nonoverlapping conformation-sensitive human MAbs (CBH-4D and e137), one derived from a broadly neutralizing antibody overlapping the CD81 binding site (e137) (42) and one derived from a nonneutralizing antibody (CBH-4D). As expected, Fab CBH-4D bound sE2 426 -717 , but no interaction between sE2 426 -717 and Fab e137 or CD81-LEL was observed (Fig. 6C) , suggesting that sE2 426 -717 adopts a native overall fold but that the binding capacity of its CD81 binding site is impaired.
The role of aa 412 to 425 in the viral cycle was further investigated by using retroviral particles pseudotyped with envelope glycoproteins (HCVpp) derived from primary HCV isolate UKN1A20.8 lacking the region encompassing aa 384 to 425. HCVpp carrying glycoproteins from this isolate were shown to be highly infectious (20) . HCVpp infectivity was ablated by the E2 ⌬aa384 -425 mutant (Fig. 6D) , in spite of the incorporation of E2 into purified HCVpp (Fig. 6E) , suggesting that the deletion of aa 384 to 425 affected the entry of retroviral pseudoparticles, which is in line with impaired CD81 binding. Since HCVpp have been shown to be more sensitive to glycoprotein mutations than HCVcc (45), we introduced the same deletion into an infectious HCVcc chimera (J6/JFH1). Despite clear evidence of intracellular replication of the virus genome (Fig. 6F) , no infectious particles were released from cells transfected with the mutant genome (Fig. 6G) . These results confirm the essential role of the antigenic site comprising aa 412 to 423 during HCV entry.
Concluding remarks. In summary, the striking structural flexibility displayed by the antigenic site at aa 412 to 423 confirms that this region of E2 is not part of a structured domain. As described above, the glycan chain attached to N 417 requires the peptide chain to adopt an extended conformation to allow binding of MAb 3/11. The neutralizing activity of MAb 3/11 indicates that this extended conformation is present at the surface of infectious particles during virus entry and that the N-terminal 40 residues within E2 are structurally flexible. This is in agreement with the recently observed elevated deuterium exchange rates for the N-terminal 72 residues within E2 (10) and with the finding that the reported conformation of the E2 ectodomain core front layer (corresponding to aa 412 to 491) is likely to be partially induced by MAb AR3C binding (11) .
The structural flexibility of this antigenic site is likely to contribute to its reduced immunogenicity in patients (22, 25) . Human immunodeficiency virus (HIV) has been reported to utilize conformational flexibility in the CD4 binding site within the envelope protein gp120 as an immune evasion mechanism (reviewed in reference 57). For NAbs targeting the protruding (P) domain of the capsid of murine norovirus type 1 (MNV-1), escape mutants were shown to switch conformations in the two structurally flexible P domain loops, resulting in a deterioration of the stereochemical fit of the NAb paratope to the P domain (58) . It is tempting to speculate that HCV also employs structural flexibility as an immune evasion mechanism to prevent NAbs targeting this conserved receptor binding domain from being elicited. While our structural analysis suggests that the antigenic site spanning aa 412 to 423 can adopt at least two different conformations, the majority of monoclonal antibodies characterized so far recognize the ␤-hairpin. In addition, our SPR analysis highlights differences in the kinetic behaviors of MAbs 3/11 and AP33 binding wt sE2 and sE2 ⌬HVR1, respectively, suggesting that the ␤-hairpin might be the predominant conformation that could be stabilized by interactions within E2 and/or E1 at the virus surface. Our data have implications for vaccine design, because the flexibility in this antigenic site could prevent this epitope from being an ideal candidate for an efficient vaccine. In view of a number of potent broadly neutralizing antibodies directed against different regions within E2 (23, 42, (59) (60) (61) (62) , other antigenic sites could potentially be more advantageous for vaccine design. Our results provide insights into the recognition of E2 by broadly neutralizing antibodies and are an important step on the way to developing an efficient vaccine against HCV.
